Sam Brusco, Associate Editor07.18.22
Medical device contract manufacturing firm Mediliant has appointed Rob Debney as its new VP of sales and marketing.
Debney began his tenure in the medical device industry with Stryker, where he worked for their UK Trauma and Extremity sales team. He then relocated to France to work for Orchid, culminating the role of director of international business development.
Over the past year he has been consulting for several international spine, trauma, and extremities firms. Before this he was a professional athlete, working as a referee for the Rugby Football Union.
“We’re excited to have Rob join the Executive team to lead our commercial efforts,” Mediliant Group CEO Matt Burba told the press. “Rob brings a passion for customers, a broad international knowledge of the industry, and a contagious enthusiasm for building winning teams. We expect Rob and the international commercial team to build mutually beneficial partnerships with our customers as we continually expand the value we deliver through our strategy to become a top-tier spine, trauma, and extremities contract manufacturer."
“Rob’s expertise, considerable leadership and management skills, and his ability to work in a high-pressure environment makes him the ideal candidate for his role on the Executive team,” Burba continued. “As the company continues to build momentum, expand capabilities, and enhance customer experiences, the growth of the leadership team plays an important role in the overall success.”
Matt Burba was named CEO of Mediliant in May.
Debney began his tenure in the medical device industry with Stryker, where he worked for their UK Trauma and Extremity sales team. He then relocated to France to work for Orchid, culminating the role of director of international business development.
Over the past year he has been consulting for several international spine, trauma, and extremities firms. Before this he was a professional athlete, working as a referee for the Rugby Football Union.
“We’re excited to have Rob join the Executive team to lead our commercial efforts,” Mediliant Group CEO Matt Burba told the press. “Rob brings a passion for customers, a broad international knowledge of the industry, and a contagious enthusiasm for building winning teams. We expect Rob and the international commercial team to build mutually beneficial partnerships with our customers as we continually expand the value we deliver through our strategy to become a top-tier spine, trauma, and extremities contract manufacturer."
“Rob’s expertise, considerable leadership and management skills, and his ability to work in a high-pressure environment makes him the ideal candidate for his role on the Executive team,” Burba continued. “As the company continues to build momentum, expand capabilities, and enhance customer experiences, the growth of the leadership team plays an important role in the overall success.”
Matt Burba was named CEO of Mediliant in May.